There are currently 1005 clinical trials in San Antonio, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Health Science Center at San Antonio, GSK Investigational Site, Pfizer Investigational Site and Methodist Children's Hospital of South Texas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
NCT05364307
Recruiting
Apheleia-001 is a prescreener that aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and blood-based biomarkers to distinguish appropriate participants for referral to a therapeutic AD clinical trial.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
12/28/2022
Locations: Clinical Trials of Texas, San Antonio, Texas
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy
Gender:
All
Ages:
18 years and above
Trial Updated:
12/09/2022
Locations: GSK Investigational Site, San Antonio, Texas
Conditions: Neoplasms
Register for Updates
CONTOURA vs WFO Ablation PRK & LASIK
NCT05037370
Recruiting
This is a prospective randomized contralateral double-masked study. Each patient will be randomized as to which eye undergoes wave-front optimized (WFO) vs. wave-front guided (WFG) during Photorefractive keratectomy (PRK) or Laser-assisted in situ Keratomileusis (LASIK) surgery to determine which ablation profile provides the best visual outcome.
Gender:
All
Ages:
Between 21 years and 50 years
Trial Updated:
12/08/2022
Locations: Joint Warfighter Refractive Surgery Center at WHASC, San Antonio, Texas
Conditions: Refractive Surgery
Register for Updates
Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options
NCT03583164
Recruiting
A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.
Gender:
All
Ages:
16 years and above
Trial Updated:
11/30/2022
Locations: The University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Invasive Fungal Infections
Register for Updates
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
NCT04012996
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
All
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: Texas Spine Care Center, San Antonio, Texas
Conditions: Symptomatic Cervical Disc Disease
Register for Updates
An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
NCT05566717
Recruiting
Evaluate the association between level of decreased corneal sensitivity and diabetic retinopathy severity scale
Gender:
All
Ages:
18 years and above
Trial Updated:
09/30/2022
Locations: Medical Center Ophthalmology Associates, San Antonio, Texas
Conditions: Diabetic Retinopathy, Neurotrophic Keratitis
Register for Updates
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
NCT04375813
Recruiting
eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized controlled trial of long-term (one year) prevention with eRapa versus placebo. The primary hypothesis is that eRapa decreases the risk of cancer relapse for patients with NMIBC. Secondary hypotheses are that eRapa can improve certain immune parameters and improve cognition and physical function without advers... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/14/2022
Locations: South Texas Veterans Health Care System (recruiting for treatment at UT Health San Antonio), San Antonio, Texas +1 locations
Conditions: Non-muscle Invasive Bladder Cancer
Register for Updates
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04880187
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: American Research Corporation, San Antonio, Texas +2 locations
Conditions: Non Alcoholic Steatohepatitis (NASH)
Register for Updates
An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection
NCT03988855
Recruiting
This is an open-label study to evaluate the safety, efficacy, and PK of DNV3837 at a dose of 1.5 mg/kg actual body weight(BW)/day administered via IV infusion in subjects with CDI. The study will be conducted in 2 subsequent parts. In Part 1 of the study, 10 subjects of either sex with severe or non-severe CDI will be enrolled to receive DNV3837. In Part 2 of the study, up to 30 subjects with severe or non-severe CDI will be enrolled to receive DNV3837. In both parts of the study, treatment i... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/06/2022
Locations: Southern Star Research Institute, LLC., San Antonio, Texas
Conditions: Clostridium Difficile (C. Difficile)
Register for Updates
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
NCT04666129
Recruiting
This study is being conducted to assess the safety and tolerability of relugolix with other agents approved for use in combination with androgen deprivation therapy (ADT) for a 12-week treatment period and an additional 40-week safety extension period in men with prostate cancer, either metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic or metastatic castration-resistant prostate cancer (nmCRPC or mCRPC).
Gender:
Male
Ages:
18 years and above
Trial Updated:
09/02/2022
Locations: Urology San Antonio, San Antonio, Texas
Conditions: Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Register for Updates
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
NCT04909021
Recruiting
This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as a nasal spray. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 6 and 24 months who are seronegative to RSV.
Gender:
All
Ages:
Between 6 months and 36 months
Trial Updated:
08/01/2022
Locations: Benchmark Research, San Antonio, Texas
Conditions: Respiratory Syncytial Virus (RSV)
Register for Updates
LITMUS Imaging Study
NCT05479721
Recruiting
The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD). It aims to evaluate the diagnostic performance of imaging biomarkers (ultrasound elastography and magnetic resonance biomarkers) against NAFLD histological scores in a cross-sectional analysis and the natural history of NAFLD in a longitudinal study.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
07/26/2022
Locations: Pinnacle Clinical Research, San Antonio, Texas
Conditions: NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
Register for Updates